Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.77)
# 80
Out of 5,090 analysts
26
Total ratings
72.73%
Success rate
34.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Assumes: Overweight | $9 | $2.67 | +237.08% | 1 | Nov 18, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $7.92 | +228.28% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $109.60 | +16.79% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $18.31 | +14.69% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $16.51 | +154.39% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $79.64 | -5.83% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $22.98 | +56.66% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $43.30 | +27.02% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $9.63 | +14.23% | 1 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $18.20 | +97.80% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.53 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.64 | +72.41% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.37 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $69.56 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $28.13 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.20 | - | 1 | Oct 31, 2022 |
Black Diamond Therapeutics
Nov 18, 2025
Assumes: Overweight
Price Target: $9
Current: $2.67
Upside: +237.08%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $7.92
Upside: +228.28%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $109.60
Upside: +16.79%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $18.31
Upside: +14.69%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $16.51
Upside: +154.39%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $79.64
Upside: -5.83%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $22.98
Upside: +56.66%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $43.30
Upside: +27.02%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $9.63
Upside: +14.23%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.20
Upside: +97.80%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.53
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.64
Upside: +72.41%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $69.56
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $28.13
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.20
Upside: -